GPCR Relative Valuation
GPCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GPCR is overvalued; if below, it's undervalued.
Historical Valuation
Structure Therapeutics Inc (GPCR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -34.32. The fair price of Structure Therapeutics Inc (GPCR) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 66.19 USD , Structure Therapeutics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：66.19
Fair
Undervalued
-43.34
PE
1Y
3Y
5Y
-11.92
EV/EBITDA
Structure Therapeutics Inc. (GPCR) has a current EV/EBITDA of -11.92. The 5-year average EV/EBITDA is -3.96. The thresholds are as follows: Strongly Undervalued below -12.25, Undervalued between -12.25 and -8.11, Fairly Valued between 0.19 and -8.11, Overvalued between 0.19 and 4.34, and Strongly Overvalued above 4.34. The current Forward EV/EBITDA of -11.92 falls within the Undervalued range.
-11.87
EV/EBIT
Structure Therapeutics Inc. (GPCR) has a current EV/EBIT of -11.87. The 5-year average EV/EBIT is -7.36. The thresholds are as follows: Strongly Undervalued below -16.70, Undervalued between -16.70 and -12.03, Fairly Valued between -2.69 and -12.03, Overvalued between -2.69 and 1.98, and Strongly Overvalued above 1.98. The current Forward EV/EBIT of -11.87 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Structure Therapeutics Inc. (GPCR) has a current PS of 0.00. The 5-year average PS is 4.95. The thresholds are as follows: Strongly Undervalued below -15.07, Undervalued between -15.07 and -5.06, Fairly Valued between 14.95 and -5.06, Overvalued between 14.95 and 24.96, and Strongly Overvalued above 24.96. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-22.16
P/OCF
Structure Therapeutics Inc. (GPCR) has a current P/OCF of -22.16. The 5-year average P/OCF is -12.76. The thresholds are as follows: Strongly Undervalued below -22.19, Undervalued between -22.19 and -17.48, Fairly Valued between -8.05 and -17.48, Overvalued between -8.05 and -3.34, and Strongly Overvalued above -3.34. The current Forward P/OCF of -22.16 falls within the Undervalued range.
-14.80
P/FCF
Structure Therapeutics Inc. (GPCR) has a current P/FCF of -14.80. The 5-year average P/FCF is -10.48. The thresholds are as follows: Strongly Undervalued below -22.53, Undervalued between -22.53 and -16.50, Fairly Valued between -4.46 and -16.50, Overvalued between -4.46 and 1.56, and Strongly Overvalued above 1.56. The current Forward P/FCF of -14.80 falls within the Historic Trend Line -Fairly Valued range.
Structure Therapeutics Inc (GPCR) has a current Price-to-Book (P/B) ratio of 5.37. Compared to its 3-year average P/B ratio of 3.68 , the current P/B ratio is approximately 46.03% higher. Relative to its 5-year average P/B ratio of 3.68, the current P/B ratio is about 46.03% higher. Structure Therapeutics Inc (GPCR) has a Forward Free Cash Flow (FCF) yield of approximately -4.17%. Compared to its 3-year average FCF yield of -6.68%, the current FCF yield is approximately -37.56% lower. Relative to its 5-year average FCF yield of -6.68% , the current FCF yield is about -37.56% lower.
5.37
P/B
Median3y
3.68
Median5y
3.68
-4.17
FCF Yield
Median3y
-6.68
Median5y
-6.68
Competitors Valuation Multiple
The average P/S ratio for GPCR's competitors is 231.04, providing a benchmark for relative valuation. Structure Therapeutics Inc Corp (GPCR) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of GPCR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of GPCR in the past 1 year is driven by Unknown.
People Also Watch
GO
Grocery Outlet Holding Corp
9.645USD
5.53%
HIMX
Himax Technologies Inc
8.325USD
0.54%
BCRX
BioCryst Pharmaceuticals Inc
7.535USD
-4.86%
UA
Under Armour Inc
5.825USD
6.10%
WS
Worthington Steel Inc
36.24USD
3.40%
SSRM
SSR Mining Inc
21.56USD
-2.97%
MCRI
Monarch Casino & Resort Inc
94.32USD
2.04%
CSGS
Csg Systems International Inc
79.46USD
0.08%
Frequently Asked Questions
Is Structure Therapeutics Inc (GPCR) currently overvalued or undervalued?
Structure Therapeutics Inc (GPCR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -34.32. The fair price of Structure Therapeutics Inc (GPCR) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 66.19 USD , Structure Therapeutics Inc is Undervalued By Fair .
What is Structure Therapeutics Inc (GPCR) fair value?
GPCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Structure Therapeutics Inc (GPCR) is between +Inf to +Inf according to relative valuation methord.
How does GPCR's valuation metrics compare to the industry average?
The average P/S ratio for GPCR's competitors is 231.04, providing a benchmark for relative valuation. Structure Therapeutics Inc Corp (GPCR) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Structure Therapeutics Inc (GPCR) as of Jan 08 2026?
As of Jan 08 2026, Structure Therapeutics Inc (GPCR) has a P/B ratio of 5.37. This indicates that the market values GPCR at 5.37 times its book value.
What is the current FCF Yield for Structure Therapeutics Inc (GPCR) as of Jan 08 2026?
As of Jan 08 2026, Structure Therapeutics Inc (GPCR) has a FCF Yield of -4.17%. This means that for every dollar of Structure Therapeutics Inc’s market capitalization, the company generates -4.17 cents in free cash flow.
What is the current Forward P/E ratio for Structure Therapeutics Inc (GPCR) as of Jan 08 2026?
As of Jan 08 2026, Structure Therapeutics Inc (GPCR) has a Forward P/E ratio of -43.34. This means the market is willing to pay $-43.34 for every dollar of Structure Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Structure Therapeutics Inc (GPCR) as of Jan 08 2026?
As of Jan 08 2026, Structure Therapeutics Inc (GPCR) has a Forward P/S ratio of 0.00. This means the market is valuing GPCR at $0.00 for every dollar of expected revenue over the next 12 months.